Serum Institute Of India Covishield
- All
- News
- Videos
-
Supreme Court Agrees To Hear Plea Over Covishield Side-Effect Concern
The Supreme Court will hear a petition on a rare side-effect associated with the COVID vaccine developed jointly by British pharma giant AstraZeneca and Oxford University, manufactured by the Serum Institute of India and sold in India as Covishield.
-
Couple Allege Daughter Died After Taking Covishield, To Sue AstraZeneca
The parents of a young woman who died allegedly after being given Covishield are planning to sue the world's largest vaccine maker and the British pharma giant that had developed the vaccine during the Covid pandemic.
-
Serum Institute Restarts Manufacturing Of COVID-19 Vaccine Covishield
Serum Institute of India CEO Adar Poonawalla on Wednesday said the company has restarted manufacturing of COVID-19 vaccine Covishield amid rising numbers of cases of the virus infection.
-
Serum Institute Restarts Production Of Covishield Vaccine After Cases Rise
Serum Institute of India CEO Adar Poonawalla on Wednesday said the company has restarted manufacturing of COVID-19 vaccine Covishield amid rising numbers of cases of the virus infection.
-
Exclusive: "Telling China To Take Our Booster," Adar Poonawalla Tells NDTV
The Serum Institute of India is working to market its two key vaccines for Covid -- Covovax and Covishield -- in China, which is seeing a resurgence of the pandemic.
-
Serum Institute To Provide 2 Crore Covishield Doses To Centre For Free
The Serum Institute of India has offered two crore doses of Covishield vaccine to the central government free of cost amid a rise in COVID-19 cases in some countries, official sources said today.
-
"People Fed Up Of Covid, Vaccines. I Am Also Fed Up": Adar Poonawalla
Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla, on Thursday said the vaccine manufacturer stopped the production of Covishield vaccine starting December 2021.
-
Serum Institute Halts Vaccine Production Over Millions Of Unused Doses
Serum Institute of India Ltd., the world's largest vaccine manufacturer and a key supplier of Covid-19 inoculations to developing countries, has stopped making fresh batches of shots after its stockpile grew to 200 million doses amid a global supply
-
Covishield, Covaxin Prices Cut To Rs 225 Day Before Booster Drive Begins
Serum Institute of India CEO Adar Poonawalla and Bharat Biotech cofounder Suchitra Ella today said that the decision was taken after discussions with the Centre.
-
100 Crore Covishield Doses Given In India, Abroad, Says Vaccine Maker
Over 100 crore Covishield doses have been given in India and abroad which is a testimony of its safety and efficacy, Serum Institute has informed the DCGI
-
With 1.25 Billion Jabs, Adar Poonawalla's Covishield Seeks Full Clearance
Adar Poonawalla's Serum Institute Of India has applied to the country's drug regulator and the health ministry for full approval of its COVID-19 vaccine Covishield, the chief executive said on Friday.
-
Drug Regulator Seeks More Data Over Approval For Covishield Booster: Report
An expert panel of India's central drug authority reviewed Serum Institute's application for approval of Covishield as booster dose against COVID-19 on Friday.
-
"In Dilemma That I Never Imagined": Adar Poonawalla On Covishield Output
With not enough orders for Covishield from the central government, Serum Institute of India (SII) CEO Adar Poonawalla on Tuesday said the company is looking at slashing the monthly production of vaccines by at least 50 percent.
-
Omicron-Specific Booster Shot Possible, Says Adar Poonawalla To NDTV: Highlights
As new Covid strain 'Omicron' raises alarm across the globe, Adar Poonawalla, the chief of Serum Institute of India which manufactures COVID-19 vaccine Covishield, in an exclusive interview to NDTV said that Omicron-specific booster shots are possibl
-
Omicron-Specific Booster Shot Possible: Adar Poonawalla To NDTV
A designer version of Covishield, meant for new Covid variant Omicron, could be possible, Serum Institute of India chief Adar Poonawalla told NDTV. A call on will be taken in another two weeks, when more is known about the new virus, he said.
-
Supreme Court Agrees To Hear Plea Over Covishield Side-Effect Concern
The Supreme Court will hear a petition on a rare side-effect associated with the COVID vaccine developed jointly by British pharma giant AstraZeneca and Oxford University, manufactured by the Serum Institute of India and sold in India as Covishield.
-
Couple Allege Daughter Died After Taking Covishield, To Sue AstraZeneca
The parents of a young woman who died allegedly after being given Covishield are planning to sue the world's largest vaccine maker and the British pharma giant that had developed the vaccine during the Covid pandemic.
-
Serum Institute Restarts Manufacturing Of COVID-19 Vaccine Covishield
Serum Institute of India CEO Adar Poonawalla on Wednesday said the company has restarted manufacturing of COVID-19 vaccine Covishield amid rising numbers of cases of the virus infection.
-
Serum Institute Restarts Production Of Covishield Vaccine After Cases Rise
Serum Institute of India CEO Adar Poonawalla on Wednesday said the company has restarted manufacturing of COVID-19 vaccine Covishield amid rising numbers of cases of the virus infection.
-
Exclusive: "Telling China To Take Our Booster," Adar Poonawalla Tells NDTV
The Serum Institute of India is working to market its two key vaccines for Covid -- Covovax and Covishield -- in China, which is seeing a resurgence of the pandemic.
-
Serum Institute To Provide 2 Crore Covishield Doses To Centre For Free
The Serum Institute of India has offered two crore doses of Covishield vaccine to the central government free of cost amid a rise in COVID-19 cases in some countries, official sources said today.
-
"People Fed Up Of Covid, Vaccines. I Am Also Fed Up": Adar Poonawalla
Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla, on Thursday said the vaccine manufacturer stopped the production of Covishield vaccine starting December 2021.
-
Serum Institute Halts Vaccine Production Over Millions Of Unused Doses
Serum Institute of India Ltd., the world's largest vaccine manufacturer and a key supplier of Covid-19 inoculations to developing countries, has stopped making fresh batches of shots after its stockpile grew to 200 million doses amid a global supply
-
Covishield, Covaxin Prices Cut To Rs 225 Day Before Booster Drive Begins
Serum Institute of India CEO Adar Poonawalla and Bharat Biotech cofounder Suchitra Ella today said that the decision was taken after discussions with the Centre.
-
100 Crore Covishield Doses Given In India, Abroad, Says Vaccine Maker
Over 100 crore Covishield doses have been given in India and abroad which is a testimony of its safety and efficacy, Serum Institute has informed the DCGI
-
With 1.25 Billion Jabs, Adar Poonawalla's Covishield Seeks Full Clearance
Adar Poonawalla's Serum Institute Of India has applied to the country's drug regulator and the health ministry for full approval of its COVID-19 vaccine Covishield, the chief executive said on Friday.
-
Drug Regulator Seeks More Data Over Approval For Covishield Booster: Report
An expert panel of India's central drug authority reviewed Serum Institute's application for approval of Covishield as booster dose against COVID-19 on Friday.
-
"In Dilemma That I Never Imagined": Adar Poonawalla On Covishield Output
With not enough orders for Covishield from the central government, Serum Institute of India (SII) CEO Adar Poonawalla on Tuesday said the company is looking at slashing the monthly production of vaccines by at least 50 percent.
-
Omicron-Specific Booster Shot Possible, Says Adar Poonawalla To NDTV: Highlights
As new Covid strain 'Omicron' raises alarm across the globe, Adar Poonawalla, the chief of Serum Institute of India which manufactures COVID-19 vaccine Covishield, in an exclusive interview to NDTV said that Omicron-specific booster shots are possibl
-
Omicron-Specific Booster Shot Possible: Adar Poonawalla To NDTV
A designer version of Covishield, meant for new Covid variant Omicron, could be possible, Serum Institute of India chief Adar Poonawalla told NDTV. A call on will be taken in another two weeks, when more is known about the new virus, he said.
